ADC Therapeutics (ADCT) Return on Capital Employed (2021 - 2026)
ADC Therapeutics (ADCT) posted quarterly Return on Capital Employed of 53.75% for Q1 2026, down 84.0% year-on-year from 335.91% in Q1 2025, and up 5.9% on a QoQ basis from 57.12% in Q3 2025.
ADC Therapeutics (ADCT) Return on Capital Employed (2021 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Return on Capital Employed for 6 consecutive years, with 53.75% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 84.0% year-over-year to 53.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53.75% (down 84.0% YoY) and the FY2022 annual result came in at 4.54%, up 3863.0% from the prior year.
- Return on Capital Employed rose to 53.75% in Q1 2026 per ADCT's latest filing, from 57.12% in the prior quarter.
- Over the last five years, Return on Capital Employed for ADCT reached as high as 26.85% in Q2 2023 and fell as low as 59.98% in Q1 2024.
- A 5-year average of 43.79% and a median of 43.22% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 1979 bps — and 2024, when it tumbled 2507 bps.
- Year by year, Return on Capital Employed stood at 29.76% in 2022, then dropped by 17 bps to 34.79% in 2023, then slumped by 32 bps to 45.9% in 2024, then slipped by 24 bps to 57.12% in 2025, then increased by 6 bps to 53.75% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 53.75%, 57.12%, and 59.03% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | -53.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.75% |
| Sep 30, 2025 | -57.12% |
| Jun 30, 2025 | -59.03% |
| Mar 31, 2025 | -52.90% |
| Sep 30, 2024 | -45.90% |
| Jun 30, 2024 | -49.05% |
| Mar 31, 2024 | -59.98% |
| Sep 30, 2023 | -34.79% |
| Jun 30, 2023 | -26.85% |
| Mar 31, 2023 | -34.91% |
| Dec 31, 2022 | -29.76% |
| Sep 30, 2022 | -31.67% |
| Jun 30, 2022 | -40.54% |
| Mar 31, 2022 | -36.78% |
| Dec 31, 2021 | -40.60% |
| Sep 30, 2021 | -51.47% |
| Jun 30, 2021 | -60.21% |
| Mar 31, 2021 | -49.80% |